Elevage Medical Technologies’ Post

⚡ Today, we have the pleasure to announce that a patent for the core technology behind our tissue platform Nexocyte and our high-resolution 3D bioprinting system Biopixlar has been granted in the EU. 💜 The granted patent is an important step forward that lets us further advance our mission to provide the next generation of tissue solutions for drug development and regenerative medicine, changing the way we treat diseases. #Bioprinting #TissueEngineering #RegenerativeMedicine #ATMP #SingleCell #Nexocyte

🚨 Exciting News from BioStem Technologies! 🚨 We’re thrilled to announce the Notice of Allowance for our U.S. patent application covering sterile human placental allografts. This milestone solidifies our leadership in the wound care industry and highlights the innovation behind our proprietary BioREtain® process. Our commitment to advancing wound care solutions continues to set new standards, ensuring safety, and efficacy for patients. 💡 🔗 Read the full announcement here: https://shorturl.at/NODxP #BioStem #Innovation #WoundCare #BioREtain #HealingFaster #PatentSuccess #BSEM

SFBN Feed: Roivios and Caresyntax Partner to Revolutionize Renal Care Through Data-Driven Insights https://lnkd.in/g3UXbg74 NASSAU, Bahamas and SAN FRANCISCO, Jan. 9, 2025 /PRNewswire/ — Roivios, a clinical-stage medical device company, and Caresyntax, a global leader in real-world evidence (RWE) and surgical intelligence, have joined forces to revolutionize renal care. [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

SFBN Feed: VANTIS VASCULAR CLOSES $10M IN SERIES B-1 PREFERRED FINANCING https://lnkd.in/gJNCN2kN Funds will be used to initiate US commercialization of its CrossFAST™ Integrated Microcatheter Advanced Delivery System SAN JOSE, Calif., Dec. 12, 2024 /PRNewswire/ — Vantis Vascular, Inc., a pioneering medical technology company founded by physicians [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

Epitomee Medical's, Gil Cohen will discuss their needle-free platform at #PODD2024. Topic points include: - How the Eptiomee Platform enables oral delivery of significant amounts of large molecules, including proteins and peptides - How the platform boosts bioavailability, providing a game-changing alternative to traditional injection methods - How the platform precisely transports drugs to the small intestine and across the GI wall with microscopic precision, ensuring effective bioavailability Learn more about the upcoming PODD: Partnership Opportunities in Drug Delivery conference here: #PODD #needlefree #drugdevelopment #drugdelivery

🚀 𝗦𝗵𝗮𝗽𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗗𝗿𝘂𝗴 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆 𝗦𝘆𝘀𝘁𝗲𝗺𝘀 Drug delivery research demands precision, and VCM Technology is making it happen. A recent study from the Københavns Universitet - University of Copenhagen demonstrated how VCM improves sample integrity and supports real-time imaging for subcutaneous drug delivery systems. The result? More reliable insights and better research outcomes. I'm always happy to share how VCM can streamline your research and help achieve your goals. Let’s connect! 👉 Read more: https://lnkd.in/dBn9Xc3n #pharmaceuticalmanufacturing #subcutaneous #drugdelivery #samplepreparation 

Explore the latest in #medtech and #biopharma! Discover how capital limitations, surgical trends and new regulations are shaping these sectors. Read the full industry outlook by RSM senior life sciences analysts Amanda Laskey and Brian Winne: https://rsm.buzz/49GL16D

Explore the latest in #medtech and #biopharma! Discover how capital limitations, surgical trends and new regulations are shaping these sectors. Read the full industry outlook by RSM senior life sciences analysts Amanda Laskey and Brian Winne: https://rsm.buzz/4cJTR4i

Explore the latest in #medtech and #biopharma! Discover how capital limitations, surgical trends and new regulations are shaping these sectors. Read the full industry outlook by RSM senior life sciences analysts Amanda Laskey and Brian Winne: https://rsm.buzz/3VD58Nh

Revolutionizing Drug Development with 3D Bioprinting In a TEDx Talk, Kevin Vos highlighted the enormous challenges in drug development, where creating a new drug can take 12-15 years and cost up to $2 billion, with a staggering 90% failure rate in clinical trials. However, 3D bioprinting offers a promising future, enabling accurate disease modeling, personalized treatment, and even regenerative medicine. It's time to push for better outcomes and make healthcare more efficient, affordable, and humane. what are your thoughts on this innovative approach? #3DBioprinting #PharmaceuticalInnovation #HealthcareRevolution